Close Menu

NEW YORK – Decentralized molecular testing is gaining ground for SARS-CoV-2 diagnosis in India. Due in part to a robust anti-tuberculosis campaign, the testing modality has made inroads into the country's complex and tiered healthcare system during the past decade. Now, decentralized platforms from firms like MolBio Diagnostics and Cepheid, as well as newcomer Tata Group, are starting to play a significant role in COVID-19 diagnostic testing in India as well.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.